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Azathioprine is a widely used immunosuppressive drug. Genetic polymorphisms and activity
of the enzyme thiopurine methyltransferase (TPMT) have been associated with azathioprine
efficacy and toxicity in several populations. We investigated whether these associations
also exist for ANCA associated vasculitis (AAV) patients, who receive azathioprine mainte-
nance therapy after remission induction with cyclophosphamide.
Methods
207 AAV patients treated with cyclophosphamide induction and azathioprine maintenance
therapy were included and followed for 60 months. TPMT genotype and tertiles of TPMT
activity were compared to relapse free survival and occurrence of adverse events, particu-
larly leukopenia. Multivariable regression was performed to account for confounders.
Results
In univariable analysis, relapse free survival was not significantly associated with TPMT
genotype (P = 0.41) or TPMT activity (P = 0.07), although it tended to be longer in lower ter-
tiles of TPMT activity. There was no significant association of TPMT genotype and activity
with occurrence of any adverse event. In multiple regression, leukocyte counts at the end of
cyclophosphamide induction were related to risk of leukopenia during azathioprine therapy
[P<0.001; OR 0.54 (95% CI 0.43–0.68)] and risk of relapse during follow-up [P = 0.001; HR
1.17 (95% CI 1.07–1.29)] irrespective of TMPT genotype or activity.
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Conclusion
TPMT genotype and activity were not independent predictors of relapse, and could not
predict leukopenia or other adverse effects from azathioprine. Leukocyte counts after
cyclophosphamide induction were related to both outcomes, implying a greater influ-
ence of cyclophosphamide response compared to azathioprine and TPMT in AAV
patients.
Introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) refers to a group
of primary small-vessel vasculitides. The most common forms are granulomatosis with poly-
angiitis (GPA, formerly Wegener’s Granulomatosis) and microscopic polyangiitis (MPA).[1]
Induction treatment with cyclophosphamide, rituximab or mycophenolate mofetil combined
with corticosteroids can achieve remission in most AAV patients and reduce mortality, but is
associated with considerable toxicity.[2–4] For this reason, patients switch to less toxic mainte-
nance therapy after achieving remission, most frequently azathioprine.[3–5] Even with azathi-
oprine maintenance therapy, there is a risk of potentially severe adverse effects, most
frequently leukopenia and infection.[5,6] In recent years, there has been increasing interest in
personalised medicine whereby treatment is adjusted based upon characteristics of an individ-
ual patient, thereby optimizing efficacy and reducing toxicity.
Azathioprine and its metabolite 6-mercaptopurine are converted via several enzymatic
steps into 6-thioguanine nucleotides (6-TGN), the active metabolites responsible for the
immunosuppresive effect and myelotoxicity. The enzyme thiopurine methyltransferase
(TPMT) methylates several metabolites along the enzymatic pathway, thereby reducing the
amount of 6-TGN formed.[7,8] Several polymorphisms of the gene encoding TPMT have
been identified, each resulting in decreased activity of the enzyme.[7–9] Approximately 89% of
Caucasians are homozygous for wildtype TPMT alleles corresponding with normal or high
activity.11% carry a wildtype and a variant allele corresponding with intermediate TPMT
activity. Very few individuals (0.3%) are homozygous or compound heterozygous for variant
alleles resulting in absence of TPMT activity.[8,10]
Studies in several populations, mainly inflammatory bowel disease (IBD), have shown that
TPMT variant alleles and lower TPMT activity are associated with a higher risk of bone mar-
row toxicity.[7,11–13] Patients carrying two variant TPMT alleles are especially at risk for
severe myelotoxicity[11] and require either a 10-fold lower dose or alternative therapy (e.g.
methotrexate).[6,8,14] For patients with intermediate TPMT activity carrying one variant
allele, more controversy exists. Several meta-analyses have shown an increased risk of myelo-
toxicity in these patients.[12,15] While clinical trials did not find a significant reduction of tox-
icity when adjusting azathioprine or 6-mercaptopurine dose on TPMT genotype or activity,
[14,16,17] post-hoc analysis showed a significant reduction of myelotoxicity within carriers of
a variant allele.[14]
The aforementioned studies mainly involve patients with IBD, who receive azathioprine as
their main treatment drug. Since AAV patients receive azathioprine after an induction phase
with cyclophosphamide,[4] the influence of TPMT might be smaller and less relevant in this
population.
The aim of this study was to see whether TPMT genotype and activity are associated with
bone marrow toxicity and risk of relapse in AAV patients treated with azathioprine maintenance
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therapy. We expanded on an earlier study in our population[18] by taking into account the influ-
ence of cyclophosphamide induction therapy on these outcomes.
Patients and methods
Patients
For this retrospective cohort study, 377 patients, diagnosed with GPA, MPA or Renal Limited
Vasculitis (RLV) between September 1984 and August 2013 in the University Medical Center
Groningen (UMCG) and treated with oral cyclophosphamide following diagnosis, were con-
sidered for inclusion. Patients were included if they switched to azathioprine after induction of
remission and had a follow-up of at least a year. All patients have given written informed con-
sent according to the Declaration of Helsinki for participation in a large cohort study investi-
gating biomarkers (including TPMT) in relation to disease outcome in AAV. Ethical approval
for the study was granted by the local Medical Ethical Committee of the University Medical
Center Groningen (NL29354.042.10).
Treatment protocol
Following diagnosis, all patients were treated with oral cyclophosphamide (1.5–2.0 mg/kg/
day) combined with prednisolone (1mg/kg/day, max 60mg/day). Prednisolone dose was
reduced according to a standard schedule (S1 Table). After 3 months of stable remission, all
patients switched to maintenance therapy with azathioprine. The starting dose was a conver-
sion from cyclophosphamide dose to the same azathioprine dose. The target azathioprine dose
was 1.5–2.0mg/kg/day. Starting 12 months after diagnosis, azathioprine dose was reduced by
25 mg/day every 3 months. Leukocyte counts were measured 1 week after starting azathioprine
and at least every 4 weeks thereafter. During treatment,cyclophosphamide and azathioprine
dose were adjusted based on leukocyte counts (goal: leukocytes4.0109/l) in accordance with
the CYCAZAREM protocol,[5] and occurrence of infections.
Data collection
All information was collected from the patients’ records. For all patients, demographic, disease
and treatment characteristics, as well as clinical outcome data were registered. Diagnosis was
based on the 2012 Chapel Hill Consensus Conference definitions.[1] Disease activity at diag-
nosis was scored using the Birmingham Vasculitis Activity Score 1 (BVAS-1).[19] Patients
were screened for the presence of ANCA using indirect immune fluorescence (IIF), and
ANCA-specificity was determined using ELISA.
The primary endpoints of the study were relapse-free survival in months and leukopenia.
Relapse was defined as new or worsening disease activity requiring dose increase or switch of
immunosuppressive medication. Leukopenia was defined as leukocyte count<4.010^9/l.[20]
Secondary categorical endpoints were moderate leukopenia (leukocyte count<3.010^9/l),
[20] macrocytic anemia (Hb <7.5 for females and<8.0 for males; MCV>96fl), hepatotoxicity
(ASAT and/or ALAT >2x upper limit of normal, or AF >125 U/l), infection (requiring hospi-
talisation and/or antibiotics, or opportunistic e.g. CMV, VZV, HSV, and/or pneumocystis jiro-
vecii pneumonia). These endpoints were scored if they occurred at any time during
azathioprine therapy. Secondary continuous endpoints were leukocyte counts 3,6,9 and 12
months after switch to azathioprine, and the [leukocyte(109/l)][azathioprine(mg/kg/d)]
product 3,6,9 and 12 months after switch as a measure of sensitivity for azathioprine-induced
bone marrow depression.[18] Diagnosis, ANCA specificity, age at diagnosis, baseline serum
creatinine, co-trimoxazole use at switch to azathioprine (none, prophylactic or therapeutic
TPMT and azathioprine maintenance therapy for ANCA associated vasculitis
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dose), leukocyte count at switch and duration of azathioprine therapy were registered for their
potential influence on relapse. Factors registered for their potential influence on risk of leuko-
penia include prednisolone dose at switch, cyclophosphamide dose at switch, leukocyte count
at switch and azathioprine dose at switch. Prednisolone dose during azathioprine therapy was
registered to account for its influence on leukocyte counts.
Measurement of TPMT genotype and TPMT activity
Four variants of the TPMT gene, located on chromosome 6, were determined using PCR, as
described by Yates et al.[9] The genetic variants were TPMT2 (G!C translocation at nucleotide
238), TPMT3A (460G!A and 719A!G), TPMT3B (460G!A), and TPMT3C (719A!G).
TPMT activity was determined by adding 6-thioguanine to human erythrocytes in vitro,
and measuring the amount of 6-methylthioguanine formed (TPMT catalyses this reaction),
expressed in nmol 6-methylthioguanine formed per gram haemoglobin per hour (nmol/gHb/
hr).[21] In the majority of patients (67%), TPMT genotype and activity were measured after
starting azathioprine treatment. In some patients (33%), these were measured before starting
azathioprine. The date of blood withdrawal for TPMT measurement was registered for all
patients.
Statistics
Statistical analysis was done using SPSS Statistics 22 (IBM Corporation, New York, US).
Data are shown as median + interquartile range (IQR) or number + percentage. A two-
sided P<0.05 was considered statistically significant. Univariate analysis was performed for
TPMT genotypes and tertiles of TPMT activity (tertiles determined based on equal numbers of
patients per group) using a Log Rank test for relapse free survival (up to 60 months after diag-
nosis), Fisher’s exact test or Chi Square test for risk of adverse events, and Mann-Whitney or
Kruskal-Wallis test for leukocyte count and [leukocyte][azathioprine] product. Multivariate
analysis was performed with relapse-free survival, risk of leukopenia and leukocyte counts as
outcome variable, using Cox regression, logistic regression and linear regression, respectively.
Possible predictors in the analysis were TPMT genotypes, tertiles of TPMT activity and poten-
tial influencing factors for the respective outcomes mentioned under ‘data collection’. A for-
ward stepwise model was used, where variables were included as covariates based on a
univariate P<0.05 and excluded on a multivariate P-value >0.10. Non-proportional hazards
for predictors in Cox regression were accounted for by adding a time-by-predictor interaction
variable to the model.[22]
Results
Patients and TPMT genotype and activity
207 patients were included in the analysis.(Fig 1) Demographic and disease characteristics, as
well as distribution of TPMT genotypes and TPMT activity, are shown in Table 1.
TPMT activity approximated a Gaussian distribution (Fig 2). TPMT activity was signifi-
cantly lower in carriers of TPMT3A (43.9; IQR 40.6–49.5 nmol/gHb/hr) and TPMT3C (43.5
nmol/gHb/hr) compared to patients with a homozygous normal genotype (81.4; IQR 73.5–
92.2) nmol/gHb/hr)(P<0.001). TPMT activity was divided in tertiles based on the number of
patients. The lowest tertile (T1) contains patients with TPMT activity74.5, the second tertile
(T2) contains patients with TPMT activity 74.6–86.4 and the highest tertile (T3) contains
patients with TPMT activity86.5 nmol/gHb/hr. None of the characteristics differed between
TPMT genotypes or tertiles of TPMT activity, except azathioprine dose at switch, which was
TPMT and azathioprine maintenance therapy for ANCA associated vasculitis
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significantly lower in patients with heterozygous TPMT genotype (1.0, IQR 0.7–1.4 mg/kg/
day) compared to patients with normal genotype (1.5, IQR 1.1–1.8 mg/kg/day) (P = 0.001).
Azathioprine starting dose was not significantly related to measurement of TPMT status prior
to (n = 68) or after (n = 139) start of azathioprine therapy (P = 0.92), even when specifically
analyzing patients with a heterozygous TPMT genotype (P = 0.28). As expected from the treat-
ment protocol, azathioprine starting dose showed a strong positive correlation with cyclophos-
phamide dose at switch (Rho = 0.70, P<0.001). No patients were treated with
6-mercaptopurin.
Relapse free survival
Within 5 years after diagnosis, 6 of 19 patients (32%) with heterozygous TPMT genotype expe-
rienced a relapse, compared to 84 of 188 patients (45%) with normal TPMT genotype. There
was no significant difference in relapse-free survival (P = 0.30) between TPMT genotypes (Fig
3A).
Tertiles of TPMT activity showed a negative trend with relapse-free survival (P = 0.07) (Fig
3B). In the lowest tertile (T1), 34% of patients experienced relapse within 5 years, compared to
47% in the middle tertile (T2) and 50% in the highest tertile (T3). Relapse free survival was still
not significantly related to TPMT genotype (P = 0.39) and tertiles of TPMT activity (P = 0.21)
after exclusion of patients intolerant to azathioprine.
In Cox regression, TPMT genotypes (P = 0.39), tertiles of TPMT activity (P = 0.24), co-tri-
moxazole use (P = 0.15), age (P = 0.69) and diagnosis (P = 0.94) were not significantly related
to the occurrence of relapse. ANCA specificity (P = 0.003), duration of azathioprine therapy
(P<0.001), serum creatinine at baseline (P = 0.007) and leukocyte count at switch (P = 0.001)
were significantly associated with relapse. Risk of relapse was higher for PR3-ANCA positive
patients (Hazard Ratio (HR)3.1; 95% CI 1.5–6.6), and for patients with a higher leukocyte
count after cyclophosphamide induction (HR 1.17; 95% CI 1.07–1.29). Risk of relapse was
Fig 1. Flow-chart of patient selection.
https://doi.org/10.1371/journal.pone.0195524.g001
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lower for patients with a longer duration of azathioprine maintenance (HR 0.91; 95%CI 0.87–
0.96), and patients with a baseline creatinine >1.24 mg/dl (HR 0.5, 95%CI 0.3–0.8). The inter-
action [azathioprine duration][time] was significant (P = 0.008) and indicated a declining
protective effect of azathioprine duration over time (HR 1.002, 95%CI 1.000–1.003). The same
variables remained significant after exclusion of patients intolerant to azathioprine (S2 Table).
Adverse events
In total, 35 patients (16%) were intolerant to azathioprine. 17 patients (8%) had gastro-intesti-
nal complaints, 17 (8%) had a febrile hypersensitivity reaction, and 1 patient (1%) had a rash.
Intolerance to azathioprine was not related to TPMT genotype (P = 0.11) or tertiles of TPMT
activity (P = 0.39). There was no significant difference between TPMT genotypes in occurrence
of mild or moderate leukopenia (Table 2). Occurrence of mild or moderate leukopenia also
did not significantly differ between tertiles of TPMT activity (Table 3).
The lowest measured leukocyte count was 1.410^9/l. Two patients had concomitant infec-
tions (PCP pneumonia and CMV antigenemia, candida stomatitis and PCP pneumonia,
respectively). In 12 patients with moderate leukopenia, azathioprine dose was reduced and in
9 patients azathioprine was (temporarily) discontinued. In all except 3 patients, moderate leu-
kopenia was incidental. In the others durations were 5, 7 and 35 days before leukocyte counts
were>3.0109/l.
Table 1. Patient characteristics.
Characteristics N (%)/mean (SD)/median (IQR)
Female 94 (45%)
Age at diagnosis (years) 57 (46–66)
Diagnosis GPA 152 (73%)
PR3-ANCA 150 (73%)
BVAS at diagnosis 18 (13–24)
Serum creatinine at baseline (mg/dl) (n = 182/207) 1.24 (0.89–2.84)
Leukocyte count at switch (109/l) (n = 187/207) 6.6 (5.5–8.3)
Co-trimoxaxole use at switch (n = 194/207)
• None 41 (21%)
• Prophylactic dose (480 mg/day) 130 (67%)
• Therapeutic dose (1920 mg/day) 23 (12%)
Cyc start dose (mg/kg/day) (n = 191/207) 1.7 (0.4)
Duration of cyc therapy (months) (n = 206/207) 5 (4–6)
Prednisolone switch dose (mg/day)(n = 188/207) 12.5 (8.1–20.0)
Azathioprine switch dose (mg/kg/day) (n = 195/207) 1.4 (0.5)
Duration of azathioprine therapy (months) (n = 204/207) 17 (7–24)
Follow-up time (months) 54 (32–60)
TPMT genotype
• No variant (1/1) 188 (91%)
• TPMT 1/3A 16 (8%)
• TPMT 1/3C 3 (1%)
TPMT activity (nmol/gHb/hr) 80.0 (17.9)
GPA granulomatosis with polyangiitis; MPA microscopic polyangiitis; RLV renal limited vasculitis; PR3 proteinase 3;
MPO myeloperoxidase; BVAS Birmingham Vasculitic Activity Score; Cyc cyclophosphamide; TPMT thiopurine
methyltransferase
https://doi.org/10.1371/journal.pone.0195524.t001
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Azathioprine starting dose was not significantly different between patients with (median
1.6; IQR 1.2–1.8 mg/kg) and without (median 1.4; IQR 0.9–1.8 mg/kg) mild leukopenia
(P = 0.08), neither between patients with (median 1.5; IQR 1.1–1.7 mg/kg) or without (median
1.5; IQR 1.1–1.8) moderate leukopenia (P = 0.65). The same goes for patients with and without
macrocytic anemia (P = 0.09), liver toxicity (P = 0.26) and infections (P = 0.69).
In logistic regression, TPMT genotype and activity were not significantly related to leuko-
penia during azathioprine therapy. Prednisolone dose and cyclophosphamide dose at switch
were also not significant. Leukocyte count at switch (i.e. at the end of induction therapy with
cyclophosphamide) remained in the model as a significant predictor of leukopenia (P<0.001),
as well as azathioprine dose at switch (P = 0.04) with a higher risk of leukopenia during azathi-
oprine therapy in patients with a lower leukocyte count at the end of cyclophosphamide ther-
apy (Odds Ratio (OR) 0.54; 95% CI 0.43–0.68), and for patients with a higher starting dose of
azathioprine (OR 2.2; 95% CI 1.0–4.6). See also S3 Table.
Leukocyte counts 3, 6, 9 and 12 months after switch to azathioprine were not significantly
different between TPMT genotypes or tertiles of TPMT activity. The [leukocyte][azathio-
prine] product was significantly lower for heterozygous patients 3 months after switch
(P = 0.03) but not at later time points (Fig 4A). The [leukocyte][azathioprine] product did not
significantly differ between tertiles of TPMT activity (Fig 4B).
In multivariate linear regression, after correction for prednisolone dose, TPMT genotype
was still not a significant predictor of leukocyte count or [leukocyte][azathioprine] product at
any time point. Tertiles of TPMT activity, on the other hand, were positively related to leuko-
cyte counts 3 months (P<0.001; b (regression coefficient of predictor) = 0.74; 95% CI 0.35–
1.14) and 9 months after switch (P = 0.04; b = 0.36; 95% CI 0.02–0.70) after correction for
prednisolone dose. Multivariate linear regression also showed a significant association of
TPMT activity tertiles with the [leukocyte][azathioprine] product 3 (P = 0.003; b = 1.20; 95%
CI 0.41–2.00), 9 (P = 0.01; b = 0.94; 95% CI 0.20–1.69) and 12 months after switch (P = 0.02;
b = 0.76; 95% CI 0.12–1.41). This indicates higher [leukocyte][azathioprine] product and
Fig 2. Distribution of TPMT activity. TPMT activity in nmol/gHb/hr for patients with normal (gray) and heterozygous (black) TPMT genotype.
https://doi.org/10.1371/journal.pone.0195524.g002
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Fig 3. Relapse free survival for TPMT genotypes and tertiles of TPMT activity. Relapse free survival after start of cyclophosphamide induction therapy.
Upper graph (3A): Variant = heterozygous TPMT variant carrier, Normal = normal genotype (wildtype TPMT). Lower graph (3B): T1 = lowest tertile,
T2 = middle tertile, T3 = highest tertile of TPMT activity.
https://doi.org/10.1371/journal.pone.0195524.g003
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therefore lower sensitivity for azathioprine-induced leukopenia in patients with higher TPMT
activity. Prednisolone dose showed a significant positive association with leukocyte counts and
the [leukocyte][azathioprine] product at every time point (P0.001).
TPMT genotype was not related to occurrence of macrocytic anemia, liver toxicity, infec-
tion, or intolerance to azathioprine (Table 2). Occurrence of these adverse events was also not
significantly different between tertiles of TPMT activity (Table 3).
Discussion
In this study, we found no significant association of TPMT genotype and TPMT activity with
relapse free survival. TPMT genotype and activity were not related to occurrence of
Table 2. Adverse events in relation to TPMT genotype.
Adverse events All n(%) Variant n(%) Normal n(%) P
All azathioprine tolerant patients 172 15 157
Missing data on leukopenia 8 0 8
0.79Leukopenia 75 (46) 6 (40) 69 (46)
• Mild leukopenia (<4109/l) 54 (33) 4 (27) 50 (34)
>0.99• Moderate leukopenia (<3109/l) 21 (13) 2 (13) 19 (13)
Missing data on macrocytic anemia 10 0 10
0.28Macrocytic anemia 74 (46) 9 (60) 65 (44)
Missing data on hepatotoxicity 8 0 8
0.26Hepatotoxicity 26 (16) 4 (27) 22 (15)
Missing data on infections 11 1 10
0.40Infection 62 (39) 7 (50) 55 (37)
Number of patients experiencing adverse events. All analyses (except for intolerance) have been done only in patients who were not intolerant to azathioprine (n = 172).
All = all patients. Variant = heterozygous TPMT variant carrier, Normal = normal TPMT genotype.
Compared between TPMT genotypes.
https://doi.org/10.1371/journal.pone.0195524.t002
Table 3. Adverse events in relation to TPMT activity.
Adverse events All n(%) T1 n (%) T2 n (%) T3 n (%) P
All azathioprine tolerant patients 172 57 55 60
Missing data on leukopenia 8 1 1 6
0.82Leukopenia 75 (46) 27(48) 23 (43) 25 (46)
• Mild leukopenia (<4109/l) 54 (33) 17 (31) 20 (37) 17 (31)
0.13• Moderate leukopenia (<3109/l) 21 (13) 10 (18) 3 (6) 8 (15)
Missing data on macrocytic anemia 10 2 2 6
0.11Macrocytic anemia 74 (46) 29 (53) 18 (34) 27 (50)
Missing data on hepatotoxicity 8 1 1 6
0.48Hepatotoxicity 26 (16) 11 (20) 6 (11) 9 (17)
Missing data on infections 11 3 1 7
0.90Infection 62 (39) 22 (41) 21 (39) 19 (36)
Number of patients experiencing adverse events. All analyses (except for intolerance) have been done only in patients
who were not intolerant to azathioprine (n = 172). All = all patients. T1 = first tertile, T2 = second tertile, T3 = third
tertile of TPMT activity.
Compared between tertiles of TPMT activity.
https://doi.org/10.1371/journal.pone.0195524.t003
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Fig 4. [leuko][aza] product over time for TPMT genotypes and tertiles of TPMT activity. [leukocyte][azathioprine] product 3,6,9 and 12 months
after switch to azathioprine. P<0.05. Upper graph (4A): Variant = heterozygous TPMT variant carrier; Normal = normal genotype (wildtype TPMT).
Lower graph (4B): T1 = lowest tertile, T2 = middle tertile, T3 = highest tertile of TPMT activity.
https://doi.org/10.1371/journal.pone.0195524.g004
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azathioprine related adverse events. Leukocyte counts at the end of cyclophosphamide induc-
tion therapy were significantly associated with both relapse free survival and occurrence of leu-
kopenia during azathioprine maintenance therapy.
Because azathioprine therapy is associated with a risk of potentially severe adverse events
such as bone marrow toxicity, several studies have focused on TPMT genotypes and activity as
predictors of these adverse events.[8,15] It has been established mainly in IBD patient popula-
tions that patients with a heterozygous TPMT genotype and lower TPMT activity are at
increased risk of developing adverse events,[8] and that pretesting for TPMT has a beneficial
effect specifically in the group of patients with one or several TPMT variants.[14] Although we
found that a lower TPMT activity was associated with a lower [leukocyte][azathioprine] prod-
uct, indicating an increased sensitivity to azathioprine-induced leukopenia, we did not find an
association of TPMT genotype and activity with bone marrow toxicity in our population of
AAV patients. This might be explained by the fact that AAV patients do not receive azathio-
prine as the main treatment drug, but as maintenance therapy after induction therapy with
cyclophosphamide.[4] The effect of cyclophosphamide on bone marrow toxicity during azathi-
oprine therapy may be greater than the effect of TPMT, as evidenced by the strong association
of leukocyte counts after cyclophosphamide treatment with both relapse free survival and leu-
kopenia during azathioprine therapy in this study, and the lack of a significant difference in
azathioprine starting dose between patients with and without leukopenia. Another explanation
may be that leukocyte counts after cyclophosphamide therapy reflect an overall bone marrow
susceptibility to the effects of both drugs.
The frequency of leukopenia in or population was relatively high compared to previous
reports, such as in the CYCAZAREM trial (30%).[5] The first reason for this is that patients
with leukopenia at the start of azathioprine therapy were also scored as having leukopenia dur-
ing azathioprine therapy. The second reason is that any leukopenia during the full duration of
azathioprine therapy was scored, compared to only the first 15 months after switch in the
CYCAZAREM trial.[5] When counting only patients that developed leukopenia within 15
months after start of azathioprine, the frequency of leukopenia (<4.0109/l) in our population
was 31%, similar to the frequency previously reported.[5]
Theoretically, patients with lower TPMT activity can achieve a higher efficacy of azathio-
prine.[8,23] Some studies indeed found an association of TPMT activity with clinical response.
[24,25] In a recently published RCT, adjusting azathioprine dose based on TPMT genotype did
not result in a difference in treatment response between intervention and control groups.[14]
Although we found that patients with TPMT variant alleles and patients with lower TPMT
activity had a higher relapse free survival, these differences were not significant, especially
when taking other predictors of relapse into account. Interestingly, higher leukocyte counts
after cyclophosphamide therapy were a strong predictor of relapse. This indicates that
response to cyclophosphamide may be a stronger predictor of clinical efficacy than TPMT.
This study has several limitations. First, although 207 patients is an impressive number for
a single center study on a rare disease such as AAV, the sample size may be insufficient to
detect relevant associations with sufficient power. This is especially true for the analyses on
TPMT genotype, since there are only 19 patients with a heterozygous TPMT genotype in our
study. Second, treating physicians were not blinded to a patient’s TPMT genotype and activity.
On the other hand, adjustment of azathioprine dose based on TPMT status was not included
in the treatment protocol, and the initial azathioprine dose of patients with heterozygous
TPMT genotype did not differ between patients whether their TPMT genotype and activity
were measured before or after azathioprine therapy. Third, the study was conducted in a ter-
tiary referral center, with some patients receiving part of their follow-up elsewhere. This
resulted in missing values on adverse effects of 11 patients. The baseline characteristics and
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induction treatment of these patients did not significantly differ from those of patients with
follow-up during azathioprine therapy. Lastly, the ethnicity for patients was not registered,
although over 95% of patients in our study population are estimated to be Caucasian. As we
only genotyped for TPMT variants common in Caucasians, some non-Caucasian patients
might have reduced TPMT activity resulting from an untyped TPMT variant. This could theo-
retically result in underestimation of the effects from TPMT genotype.
The study also has several strengths. It was performed in a single center and all patients
were treated according to the same protocol, thereby eliminating between-center differences
in treatment and followup measurements. Also, compared to an earlier study on TPMT geno-
type and activity in AAV patients from our population,[18] this study has a larger sample size
(207 compared to 108), has a longer duration of follow-up and includes multivariable analyses
to account for induction treatment and other factors influencing disease free survival and risk
of adverse events.
In conclusion, TPMT genotype and activity were not related to azathioprine efficacy and
toxicity in our retrospective cohort of AAV patients receiving azathioprine maintenance ther-
apy. Response to cyclophosphamide, on the other hand, may have a stronger predictive value
on these outcomes. This should be confirmed in a sufficiently large multicenter study.
Supporting information
S1 Table. Tapering scheme for prednisolone. † Start tapering earlier when in full remission
for 2weeks, <6wks of therapy.
(DOCX)
S2 Table. Cox regression for 5 year relapse free survival. Cox regression analysis for 5 year/
60 month relapse free survival for non-azathioprine intolerant patients (n = 172). Variables for
the final model were selected using a forward stepwise method (inclusion if univariate P<0.05,
exclusion if multivariate P>0.1). ANCA specificity, duration of azathioprine therapy, creati-
nine at baseline and leukocyte count after cyclophosphamide induction therapy were signifi-
cantly associated with risk of relapse. P<0.05; P<0.01; P<0.001.
(DOCX)
S3 Table. Logistic regression for risk of leukopenia. Logistic regression for risk of leukopenia
(leukocyte count<4.0109/l) for non-intolerant patients (n = 172). Variables for the final
model were selected using a forward stepwise method (inclusion if univariate P<0.05, exclu-
sion if multivariate P>0.1). A higher leukocyte count after cyclophosphamide induction ther-
apy was associated with a lower risk of leukopenia, and a higher starting dose of azathioprine
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